BLU News and Press, BELLUS Health Inc. From 07/14/22

After the company announced the launch and pricing of its latest public stock offering, shares of BELLUS Health (NASDAQ: BLU) are down by around 12.1% as of 10:53 a.m. Thursday. The offering is for 16,540,541 shares, priced at $9.25 per share, which is currently a slight premium ove...

ContraFect ( CFRX ) -77% as data safety board recommends ending co's DISRUPT trial . BELLUS Health ( BLU ) -10% on pricing $153M stock offering in Canada, U.S. Telefonaktiebolaget LM Ericsson ( ERIC ) -9% on Q2 earnings release . Therape...

In connection with its previously announced public offering of common shares in Canada and the United States, BELLUS Health ( NASDAQ: BLU ) has entered into an underwriting pact to offer 16,540,541 common shares at offering price of $9.25/common share. Offering is expected...

Common Shares Priced at US$9.25 per Share In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX a...

BELLUS Health ( NASDAQ: BLU ) on Wednesday announced the launch of a public offering of shares in Canada and the U.S. The Canadian biotech said it intends to use the net proceeds of the offering to primarily fund the R&D activities of its cough candidate BLU-5937. ...

Shares of BELLUS Health ( NASDAQ: BLU ) have added 5.2% to $10.17 in afternoon trading and, if the gains hold, the stock is on track to post a second straight positive session . The Canadian biotech on Tuesday outlined its plans for the phase 3 development of its...

Following an End-of-Phase 2 with the FDA, Canadian biotech BELLUS Health ( NASDAQ: BLU ) announced plans to conduct two pivotal trials as part of its Phase 3 development for lead candidate BLU-5937 in refractory chronic cough (“RCC”). The CALM-1 and CALM-2 st...

- CALM Phase 3 program consists of two pivotal trials (CALM-1 and CALM-2), with primary efficacy endpoint of 24-hour cough frequency measured at 12- and 24-weeks, respectively - - The Company has reached alignment with FDA on the primary efficacy endpoint of 24H cough frequenc...

Rising interest rates affect businesses — more so for growth-oriented companies. Technology is the hardest-hit sector in an inflationary period, as tech companies rely on borrowing to pursue growth initiatives. However, there are exceptions. Some companies — not only in tech b...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indicati...